GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » E10

Akari Therapeutics (FRA:CLA) E10 : €-58.53 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Akari Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.761. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-58.53 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-24), Akari Therapeutics's current stock price is €2.82. Akari Therapeutics's E10 for the quarter that ended in Mar. 2024 was €-58.53. Akari Therapeutics's Shiller PE Ratio of today is .


Akari Therapeutics E10 Historical Data

The historical data trend for Akari Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics E10 Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -53.00 -57.97 - -58.53

Competitive Comparison of Akari Therapeutics's E10

For the Biotechnology subindustry, Akari Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Shiller PE Ratio falls into.



Akari Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akari Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.761/131.7762*131.7762
=-0.761

Current CPI (Mar. 2024) = 131.7762.

Akari Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201312 0.000 98.326 0.000
201403 -57.840 99.695 -76.453
201406 -58.880 100.560 -77.158
201409 -4.720 100.428 -6.193
201412 -16.220 99.070 -21.575
201503 -3.696 99.621 -4.889
201506 -3.564 100.684 -4.665
201509 -106.920 100.392 -140.346
201512 36.720 99.792 48.489
201603 -4.553 100.470 -5.972
201606 -17.800 101.688 -23.067
201609 -0.633 101.861 -0.819
201612 -18.960 101.863 -24.528
201703 -18.700 102.862 -23.956
201706 -0.484 103.349 -0.617
201709 -16.780 104.136 -21.234
201712 -16.900 104.011 -21.411
201803 -1.423 105.290 -1.781
201806 -17.120 106.317 -21.220
201809 -4.029 106.507 -4.985
201812 -3.907 105.998 -4.857
201903 -2.850 107.251 -3.502
201906 -4.534 108.070 -5.529
201909 -2.364 108.329 -2.876
201912 -6.574 108.420 -7.990
202003 -2.694 108.902 -3.260
202006 -4.401 108.767 -5.332
202009 0.458 109.815 0.550
202012 -11.378 109.897 -13.643
202103 -2.549 111.754 -3.006
202106 -1.875 114.631 -2.155
202109 -0.531 115.734 -0.605
202112 -2.204 117.630 -2.469
202203 -1.754 121.301 -1.905
202206 -1.811 125.017 -1.909
202212 0.000 125.222 0.000
202303 0.247 127.348 0.256
202306 -0.877 128.729 -0.898
202312 0.000 129.419 0.000
202403 -0.761 131.776 -0.761

Add all the adjusted EPS together and divide 10 will get our e10.


Akari Therapeutics  (FRA:CLA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Akari Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics (FRA:CLA) Business Description

Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.